Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
1997
|
| gptkbp:ATCCode |
gptkb:B02BD09
|
| gptkbp:CASNumber |
gptkb:156547-39-8
|
| gptkbp:contraindication |
hypersensitivity to nonacog alfa
|
| gptkbp:drugClass |
recombinant coagulation factor
|
| gptkbp:form |
powder for solution for injection
|
| gptkbp:genericName |
gptkb:nonacog_alfa
|
| gptkbp:halfLife |
18-24 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
BeneFIX
|
| gptkbp:indication |
gptkb:hemophilia_B
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:mechanismOfAction |
replaces coagulation factor IX
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescribes |
perioperative management in hemophilia B
prevention and control of bleeding in hemophilia B |
| gptkbp:product |
gptkb:protein
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
nausea headache allergic reaction inhibitor development |
| gptkbp:storage |
refrigerate or store at room temperature
|
| gptkbp:UNII |
N8RGQ2S0Z3
|
| gptkbp:bfsParent |
gptkb:Wyeth
|
| gptkbp:bfsLayer |
5
|